NBRV News and Press, Nabriva Therapeutics plc From 07/01/19

WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...

In my previous Nabriva ( NBRV ) article , I said that Nabriva has two upcoming PDUFAs; the one for Contepo on April 30, 2019, and another for lefamulin on August 19, 2019. I also said that while approval is almost a certainty, the general condition of the antibiotic market makes us less convi...

Nabriva Therapeutics (NASDAQ: NBRV ) is 1% lower postmarket after filing that it's entered an open market sale agreement with Jefferies to offer up to $50M in shares . More news on: Nabriva Therapeutics plc, Healthcare stocks news, Read more ...

Nabriva Therapeutics (NASDAQ: NBRV ) is up  6%  after hours in reaction to its announcement that the European Medicines Agency (EMA) has accepted for review its marketing application for intravenous and oral formulations of lefamulin for the treatment of community-acquired pneumo...

DUBLIN, Ireland, June 24, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that the European Medicines Agency (EMA) has det...

DUBLIN, Ireland, June 21, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it will present data at ASM Microbe 2019 to...

WASHINGTON , June 20, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies will present data from their clinical...

Nabriva Therapeutics (NASDAQ: NBRV )  surges 6.2%  after submitting a Type A meeting request to the U.S. Food and Drug Administration to discuss Contepo (fosfomycin) for injection for the treatment of complicated urinary tract infections. More news on: Nabriva Therapeutics plc,...

DUBLIN, Ireland, June 19, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced today that it has submitted a Type A Meeting Request a...

The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for drug-resistant infections WASHINGTON , June 7, 2019 /PRNewswire/ -- The Antimi...